Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease; CREDO 2

Press/Media: Press / Media

Period2018 Oct 2

Media coverage

1

Media coverage

  • TitleEvaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease; CREDO 2
    Media name/outletClinical Trials.gov
    CountryUnited States
    Date18/10/2
    PersonsYongBeom Park